Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatment
Key Points
Response noted in platinum-resistant ovarian cancer across 40 patients, demonstrating a notable efficacy with bevacizumab.
49% of patients showed partial or complete response to the treatment, indicating a significant impact.
Observational analysis of treatment combining bevacizumab with single-agent chemotherapy.
Findings highlight the promise of this combination therapy, but results must be validated in larger, controlled trials.
Like
Bookmark
Share
Like
Bookmark
Share
Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatment | Synapse